Medtronic stock rated outperform due to growth potential from renal denervation and spin-off

From Yahoo Finance: 2025-06-25 14:09:00

Medtronic, Inc. (NYSE:MDT) is a top stock for early retirement portfolios, with RBC Capital reiterating a $101 price target and Outperform rating. The company’s renal denervation system is seen as an undervalued market opportunity. A survey on the Symplicity Spyral system’s potential in treating hypertension will be released before a key CMS determination on July 11, 2025.

Medtronic plc (NYSE:MDT) plans to spin off its diabetes division into MiniMed, aiming to streamline operations and focus on device-based therapeutics. The diabetes segment currently contributes about 8% to the company’s revenue. Medtronic is a leader in robotic-assisted surgery technology, with a strong focus on spine and minimally invasive treatments.

While Medtronic (NYSE:MDT) shows investment potential, some AI stocks may offer greater upside with less downside risk. An undervalued AI stock benefiting from Trump-era tariffs and onshoring trend may be worth considering. For more insights on potential investments, check out reports on the best Magic Formula Stocks for 2025 and top retirement stocks according to hedge funds.



Read more at Yahoo Finance: Medtronic Stock Rated Outperform as Renal Denervation and Spin-Off Drive Growth Potential